We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the telecommunications segment of a U. In seeking to track the performance of the S&P Telecom Select Industry Index (the index), the fund e... The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the telecommunications segment of a U. In seeking to track the performance of the S&P Telecom Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the telecommunications segment of the S&P Total Market Index (S&P TMI). Show more
The telecommunications industry is identified as a major driver of global economic recovery. Unprecedented growth in high-speed mobile Internet traffic, in particular for wireless data and...
Despite the lingering economic woes, the global telecom industry has nicely held up this year thanks to healthy growth and its traditional role as a safe haven. Still, the U.S. dominates the...
TELECOM ETFs Despite the sluggish economy, stiff competition and stringent regulations, the U.S. telecom service providers are delivering consistent growth making it attractive for betting...
Although the American economy appears to be picking up steam, earnings reports in some industries have failed to keep pace. A variety of bellwethers have either failed to beat estimates or have...
VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLBNASDAQ:TASE:NASDAQ:XTL) today announced an update to its December 8, 2008 press release regarding...
XTLbio Announces Grant of Human Monoclonal Antibody Patent Patent Covers Antibodies Directed Against Hepatitis B Virus Surface Antigen Rehovot, Israel 26 January 2004 - XTL Biopharmaceuticals...
XTLbio appoints Stockbroker and Financial Adviser Rehovot, 20 January 2004 - The Board of XTL Biopharmaceuticals Ltd ("XTLbio" or the "Company") is pleased to announce the appointment of Code...
XTLbio announces appointment of Non-Executive Director Rehovot, 12 January 2004 - XTL Biopharmaceuticals Ltd. (LSE:XTL) is pleased to announce the appointment of Peter Stalker, III, as a...
RNS Number:2908T XTL Biopharmaceuticals Limited 16 December 2003 XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today...
XTLbio R&D and Business Development Update Rehovot, Israel, 16 December 2003 - XTL Biopharmaceuticals Ltd (XTLbio) today announces an update on recent clinical progress and corporate developments...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.18 | -0.166852057842 | 107.88 | 107.88 | 103.03 | 14458 | 104.99538461 | SP |
4 | 5.3 | 5.17578125 | 102.4 | 110.38 | 100.87 | 16040 | 105.65536274 | SP |
12 | 14.53 | 15.595148653 | 93.17 | 110.38 | 91.38 | 12829 | 101.79193944 | SP |
26 | 32.13 | 42.5168717745 | 75.57 | 110.38 | 72.4153 | 10507 | 93.90818121 | SP |
52 | 37.34 | 53.0699260944 | 70.36 | 110.38 | 67.08 | 7450 | 88.6614225 | SP |
156 | 7.37 | 7.34575899532 | 100.33 | 110.38 | 64.09 | 7072 | 84.16005867 | SP |
260 | 39.22 | 57.2721962617 | 68.48 | 110.38 | 48.47 | 9234 | 85.60141395 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions